BRM421

Dry Eye Disease

Phase 3Active (Second Phase 3 trial application submitted 2025)

Key Facts

Indication

Dry Eye Disease

Phase

Phase 3

Status

Active (Second Phase 3 trial application submitted 2025)

Company

Taiwanese biotech developing regenerative peptide therapies for ophthalmology and osteoarthritis using its PDSP platform.

Drug	Company	Phase	Status
Elate Ocular®	Cambium Bio	Phase 3	Active
OT-301	Ocumension Therapeutics	Phase 2	Active
Avarept® Ophthalmic suspension 0.3%	Senju Pharmaceutical	Approved	Active
Dry Eye Care Portfolio	YD Bio	Commercial	Active
Dry Eye Studies	Oculus Research	Not Applicable (Service Provider)	Active
MediPrint Lens (Dry Eye)	MediPrint Ophthalmics	Pre-clinical/Research	Active
Tivanisiran	Sylentis	Phase 2/3	Active
A197	Aramis Biosciences	Phase 2	Active
KM102	Theratome Bio	Pre-clinical	Active
iTEAR®100 Commercialization	Olympic Ophthalmics	Commercial	Active
HydraD	EyeD Pharma	Pre-Clinical	Active
ST-100 (Vezocolmitide)	Stuart Therapeutics	Phase 3	Active